Optimization of conventional therapy in patients with IBD.
about
Microparticles as controlled drug delivery carrier for the treatment of ulcerative colitis: A brief reviewAdalimumab treatment in Crohn's disease: an overview of long-term efficacy and safety in light of the EXTEND trialClassical and recent advances in the treatment of inflammatory bowel diseasesPregnane X receptor as a target for treatment of inflammatory bowel disordersInternational Union of Basic and Clinical Pharmacology. XCVI. Pattern recognition receptors in health and diseaseDisruption of Pten speeds onset and increases severity of spontaneous colitis in Il10(-/-) miceLive Combined Bacillus subtilis and Enterococcus faecium Ameliorate Murine Experimental Colitis by ImmunosuppressionProm1 function in development, intestinal inflammation, and intestinal tumorigenesisActivation of protein tyrosine phosphatase non-receptor type 2 by spermidine exerts anti-inflammatory effects in human THP-1 monocytes and in a mouse model of acute colitisSelect a suitable treatment strategy for Crohn's disease: step-up or top-down.Histological healing after infliximab induction therapy in children with ulcerative colitisInvestigation of mitigating effect of colon-specific prodrugs of boswellic acid on 2,4,6-trinitrobenzene sulfonic acid-induced colitis in Wistar rats: Design, kinetics and biological evaluation.Therapy of steroid-resistant inflammatory bowel disease.Mechanism of action and efficacy of RX-111, a thieno[2,3-c]pyridine derivative and small molecule inhibitor of protein interaction with glycosaminoglycans (SMIGs), in delayed-type hypersensitivity, TNBS-induced colitis and experimental autoimmune enModifiable factors associated with nonadherence to maintenance medication for inflammatory bowel disease.The future developments in inflammatory bowel disease care.Histological healing in inflammatory bowel disease: a still unfulfilled promise.
P2860
Q26743907-95601827-5537-4973-B51C-8A492EF87030Q26829488-BF0874EB-542D-4C88-9F75-5EFBFC914014Q26861725-A393A52E-A01B-47BE-85F3-2BB5B0F0E88DQ26998347-0B63FAC7-1942-48CF-BD4D-B4079B6E24D0Q28081406-54A7D80E-C8B3-45CC-BD41-681A63023757Q34084483-785681FC-2ED0-41AB-AF9C-359C2AEB2761Q34222447-9B63D328-4AD5-41CF-892C-AF4B4A0F58B4Q34510512-18F94470-93CD-4783-B0A3-166BA15129AEQ34989162-4736A939-A4BF-418C-A1D8-62FAAB8F01AEQ35721537-59897DFE-AA92-497C-B05D-ACCE67E19AA5Q36105637-E3871DE4-44F3-4ADC-8897-B5C5A97E957DQ37662616-9598F444-3E77-4835-9235-F9704F99482DQ38050879-8250CB01-B9AB-470B-B736-921293217BC8Q38800987-648AED74-E5F2-40A0-A1B4-24BF0BE1A85AQ39375492-CC8D9349-B641-47B9-AB83-4F0A521C1216Q39594232-BBD26D8E-9D52-4428-9B82-0ACE0E6EEDF9Q43240077-89FC68FE-8614-4B2D-B872-FF39986D9F3E
P2860
Optimization of conventional therapy in patients with IBD.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Optimization of conventional therapy in patients with IBD.
@en
Optimization of conventional therapy in patients with IBD.
@nl
type
label
Optimization of conventional therapy in patients with IBD.
@en
Optimization of conventional therapy in patients with IBD.
@nl
prefLabel
Optimization of conventional therapy in patients with IBD.
@en
Optimization of conventional therapy in patients with IBD.
@nl
P2860
P1476
Optimization of conventional therapy in patients with IBD.
@en
P2093
Kirstin M Taylor
Peter M Irving
P2860
P2888
P304
P356
10.1038/NRGASTRO.2011.172
P407
P577
2011-10-04T00:00:00Z